Elevated lipoprotein(a) levels are associated with adverse left ventricular geometric remodeling in non-diabetic patients with essential hypertension.

IF 2.3 4区医学

Blood Pressure Pub Date : 2026-12-01 Epub Date: 2026-06-30 DOI:10.1080/08037051.2026.2694849

Tolga Kunak, Ayşegül Ülgen Kunak, İbrahim Başarıcı

{"title":"Elevated lipoprotein(a) levels are associated with adverse left ventricular geometric remodeling in non-diabetic patients with essential hypertension.","authors":"Tolga Kunak, Ayşegül Ülgen Kunak, İbrahim Başarıcı","doi":"10.1080/08037051.2026.2694849","DOIUrl":null,"url":null,"abstract":"Background: Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor associated with inflammation, endothelial dysfunction, oxidative stress, and arterial stiffness. Although elevated Lp(a) levels are linked to cardiovascular disease, their association with left ventricular (LV) geometric remodelling in hypertension remains incompletely understood. This study aimed to evaluate the relationship between serum Lp(a) levels and LV geometry in non-diabetic patients with essential hypertension.Methods: This cross-sectional observational study included 110 non-diabetic patients with essential hypertension. Patients were classified into low Lp(a) (<50 mg/dL, n=70) and elevated Lp(a) (≥50 mg/dL, n=40) groups. Comprehensive transthoracic echocardiography was performed to assess LV mass index (LVMI), relative wall thickness, and LV geometric patterns. Correlation and multivariate regression analyses were used to determine the independent association between Lp(a) levels and LV remodelling parameters.Results: Patients with elevated Lp(a) levels had significantly higher LVMI compared with those with lower levels (139.6±28.5 vs. 117.6±24.2 g/m², p<0.001). Concentric LV hypertrophy was more prevalent in the elevated Lp(a) group (55.0% vs. 20.0%, p=0.001). Serum Lp(a) levels were positively correlated with LVMI (r=0.357, p<0.001) and remained independently associated with LVMI after adjustment for clinical confounders (β=0.363, p<0.001). Elevated Lp(a) levels were also independently associated with increased odds of concentric LV hypertrophy.Conclusions: Elevated serum Lp(a) levels are independently associated with adverse LV geometric remodelling and concentric hypertrophy in non-diabetic patients with essential hypertension. Measurement of Lp(a) may provide additional information for cardiovascular risk stratification and early identification of hypertensive patients at risk for target organ damage.","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2694849"},"PeriodicalIF":2.3000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2026.2694849","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor associated with inflammation, endothelial dysfunction, oxidative stress, and arterial stiffness. Although elevated Lp(a) levels are linked to cardiovascular disease, their association with left ventricular (LV) geometric remodelling in hypertension remains incompletely understood. This study aimed to evaluate the relationship between serum Lp(a) levels and LV geometry in non-diabetic patients with essential hypertension.

Methods: This cross-sectional observational study included 110 non-diabetic patients with essential hypertension. Patients were classified into low Lp(a) (<50 mg/dL, n=70) and elevated Lp(a) (≥50 mg/dL, n=40) groups. Comprehensive transthoracic echocardiography was performed to assess LV mass index (LVMI), relative wall thickness, and LV geometric patterns. Correlation and multivariate regression analyses were used to determine the independent association between Lp(a) levels and LV remodelling parameters.

Results: Patients with elevated Lp(a) levels had significantly higher LVMI compared with those with lower levels (139.6±28.5 vs. 117.6±24.2 g/m², p<0.001). Concentric LV hypertrophy was more prevalent in the elevated Lp(a) group (55.0% vs. 20.0%, p=0.001). Serum Lp(a) levels were positively correlated with LVMI (r=0.357, p<0.001) and remained independently associated with LVMI after adjustment for clinical confounders (β=0.363, p<0.001). Elevated Lp(a) levels were also independently associated with increased odds of concentric LV hypertrophy.

Conclusions: Elevated serum Lp(a) levels are independently associated with adverse LV geometric remodelling and concentric hypertrophy in non-diabetic patients with essential hypertension. Measurement of Lp(a) may provide additional information for cardiovascular risk stratification and early identification of hypertensive patients at risk for target organ damage.

查看原文本刊更多论文

非糖尿病合并原发性高血压患者脂蛋白(a)水平升高与不良左心室几何重构相关

背景：脂蛋白(a) [Lp(a)]是一种与炎症、内皮功能障碍、氧化应激和动脉僵硬相关的心血管危险因素。尽管Lp(a)水平升高与心血管疾病有关，但其与高血压患者左心室（LV）几何重构的关系仍未充分表征。本研究旨在探讨非糖尿病合并原发性高血压患者血清Lp(a)水平与左室几何形状之间的关系。方法：本横断面观察研究纳入110例非糖尿病合并原发性高血压患者。结果：与Lp(a)水平较低的患者相比，Lp(a)水平升高的患者LVMI值显著高于Lp(a)水平较低的患者（139.6±28.5 g/m2 vs. 117.6±24.2 g/m2, p）。结论：血清Lp(a)水平升高与非糖尿病性原发性高血压患者不良左室几何重塑和同心肥厚独立相关。评估Lp(a)水平可能为心血管风险分层和识别高血压靶器官损伤风险增加的高血压患者提供额外的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Pressure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.20

自引率

5.60%

发文量

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.